275 related articles for article (PubMed ID: 24166473)
1. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
Roth M; Linkowski M; Tarim J; Piperdi S; Sowers R; Geller D; Gill J; Gorlick R
Cancer; 2014 Feb; 120(4):548-54. PubMed ID: 24166473
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography Detects
Butch ER; Mead PE; Amador Diaz V; Tillman H; Stewart E; Mishra JK; Kim J; Bahrami A; Dearling JLJ; Packard AB; Stoddard SV; Vāvere AL; Han Y; Shulkin BL; Snyder SE
Cancer Res; 2019 Jun; 79(12):3112-3124. PubMed ID: 31015228
[TBL] [Abstract][Full Text] [Related]
3. GD2-targeted immunotherapy and radioimmunotherapy.
Dobrenkov K; Cheung NK
Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
[TBL] [Abstract][Full Text] [Related]
4. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma.
Poon VI; Roth M; Piperdi S; Geller D; Gill J; Rudzinski ER; Hawkins DS; Gorlick R
Clin Sarcoma Res; 2015; 5(1):4. PubMed ID: 25642322
[TBL] [Abstract][Full Text] [Related]
5. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
6. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
7. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
[TBL] [Abstract][Full Text] [Related]
8. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
[TBL] [Abstract][Full Text] [Related]
9. Surface expression of the immunotherapeutic target G
Wiebel M; Kailayangiri S; Altvater B; Meltzer J; Grobe K; Kupich S; Rossig C
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1394. PubMed ID: 33811471
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.
Shibuya H; Hamamura K; Hotta H; Matsumoto Y; Nishida Y; Hattori H; Furukawa K; Ueda M; Furukawa K
Cancer Sci; 2012 Sep; 103(9):1656-64. PubMed ID: 22632091
[TBL] [Abstract][Full Text] [Related]
11. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
12. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma.
Sariola H; Terävä H; Rapola J; Saarinen UM
Am J Clin Pathol; 1991 Aug; 96(2):248-52. PubMed ID: 1713742
[TBL] [Abstract][Full Text] [Related]
13. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
[TBL] [Abstract][Full Text] [Related]
14. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
15. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
[TBL] [Abstract][Full Text] [Related]
16. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
Liu B; Wu Y; Zhou Y; Peng D
PLoS One; 2014; 9(4):e93576. PubMed ID: 24727660
[TBL] [Abstract][Full Text] [Related]
17. Advancing therapy for osteosarcoma.
Gill J; Gorlick R
Nat Rev Clin Oncol; 2021 Oct; 18(10):609-624. PubMed ID: 34131316
[TBL] [Abstract][Full Text] [Related]
18. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
19. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]